Cataract extraction better with ECP

Article

Endoscopic cyclophotocoagulation (ECP) and phacoemulsification cataract extraction, when combined, result in greater reduction of IOP and need for IOP-lowering medications over 3 years compared with cataract extraction by itself.

Endoscopic cyclophotocoagulation (ECP) and phacoemulsification cataract extraction, when combined, result in greater reduction of IOP and need for IOP-lowering medications over 3 years compared with cataract extraction by itself. That's according to a study by Brian A. Francis, MD, and colleagues recently published in theJournal of Cataract & Refractive Surgery.

"ECP is the first and most proven MIGS (micro-invasive glaucoma surgery). This study confirms our belief that ECP is a safe and effective adjunct to cataract surgery," said Dr Stanley J. Berke, one of the authors. "The results are encouraging from a clinical standpoint, demonstrating that by addressing glaucoma and cataract simultaneously, we are not only lowering IOP but also reducing the need for glaucoma medications, which results in reducing costs, burden, and side effects to patients."

Researchers studied 80 patients whose eyes had medically controlled open-angle glaucoma and visually significant cataract. The number of glaucoma medications they needed decreased from 1.5 ± 0.8 to 0.4 ± 0.7 (at 1 year and 2 years, respectively). At the 3-year mark, the number of medications required decreased to –0.1 ± 0.8 (n = 45). Mean IOP decreased from 18.1 mmHg ± 3.0 at baseline to 16.0 ± 2.8 mmHg at 1 year, 16.0 ± 3.3 mmHg at 2 years, and 15.4 ± 2.5 at 3 years.

Most eyes that had undergone cataract extraction alone required the same number of medications as previously used or had to use more medications over the long term. Additionally, researchers found that "adding ECP did not increase the risk for serious complications compared with cataract extraction alone."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.